We sought to identify the risk factors predicting the development of dilated cardiomyopathy (DCM) in patients with isolated congenital complete atrioventricular block (CCAVB). BACKGROUND Recently evidence has emerged that a subset of patients with CCAVB develop DCM.
The prognosis for children with congenital complete atrioventricular block (CCAVB) has been considered relatively benign, with a normal life-expectancy, although the majority of patients eventually require pacemaker implantation (1) . However, evidence has recently emerged that a subset of these patients develop dilated cardiomyopathy (DCM) despite early pacemaker implantation (2) . Most reported patients were diagnosed in utero to have CCAVB associated with maternal autoantibodies directed against SSA/Ro and SSB/La ribonucleoproteins (3) . The SSA/Ro and SSB/La antibody-induced injury to the fetal conducting system of the heart can cause isolated CCAVB. This manifestation is well-described (4), but associated DCM is less well studied (2) .
The purposes of this retrospective study were to investigate the prognostic signs in isolated CCAVB and to identify risk factors that may predict the development of DCM in a subgroup of these patients. We studied all children diagnosed with isolated CCAVB in the participating medical centers since 1972, focusing on patients who received a pacemaker and patients who subsequently developed DCM in the follow-up period.
Hospital of Philadelphia. Echocardiograms during pregnancy and/or additional electrocardiographic recordings during infancy confirmed complete and permanent atrioventricular (AV) block. A total of 149 patients with isolated CCAVB were studied after echocardiographic confirmation of normal cardiac anatomy. Pacemakers were implanted in 111 patients during follow-up. To evaluate the effect of pacing in patients with CCAVB, the 38 patients with CCAVB who did not undergo pacing were excluded from the analysis. However, none of these 38 patients developed DCM over 7 Ϯ 6 years.
Study patients were assigned to two groups according to whether they subsequently developed DCM (CCAVB/ DCM group) or not (CCAVB group). The CCAVB/DCM group included nine patients who developed DCM after the diagnosis of isolated CCAVB was made. No patient was diagnosed with DCM at the time the CCAVB was first diagnosed. The CCAVB group consisted of the remaining 102 patients with isolated CCAVB and a pacemaker, but without signs or symptoms of cardiomyopathy. Clinical data and definitions. Available demographic data of the study cohort, including gender, age at diagnosis of AV block, heart rate at initial cardiac evaluation and the presence or absence of maternal autoantibodies to 48-kd SSB/La, 52-kd SSA/Ro and 60-kd SSA/Ro ribonucleoproteins, were retrospectively reviewed. Information on the presence of fetal hydrops, mode of delivery, birth weight, gestational age at birth, heart rate and condition at birth was also reviewed. Heart rate and age at pacemaker implantation were documented. Abstracted data included pacemaker mode, pacemaker complications and pacemaker reimplantations.
All available echocardiograms performed in utero and during the neonatal period, infancy, childhood and adolescence were reviewed. Left ventricular end-diastolic dimension (LVEDD) and left ventricular end-systolic dimension (LVESD) were measured, and p values (percentile of heart size corrected for weight) were estimated for every LVEDD (5) before and after the cardiomyopathy was diagnosed. Shortening fraction (SF) was calculated as (LVEDD Ϫ LVESD)/LVEDD ϫ 100% (6) . Chest radiographs were reviewed for cardiac enlargement, pulmonary venous congestion, pulmonary edema, atelectasis and/or pleural effusions. Heart size was expressed as the cardiothoracic (CT) ratio and graded for each individual patient. A CT ratio Ͼ0.60 indicated cardiomegaly in infants Յ1 month of age. In children Ͼ1 month old, a CT ratio Ͼ0.50 indicated cardiomegaly and was categorized as mild (CT ratio 0.50 to 0.60), moderate (CT ratio of 0.60 to 0.65) or severe (CT ratio 0.65) (7) . Dilated cardiomyopathy was defined as LVEDD in the Ͼ97th percentile with SF Ͻ25% (8). Other identifiable causes of ventricular dysfunction (i.e., myocarditis) were not encountered. Analysis of data. Comparisons between the CCAVB/ DCM group and the CCAVB group were performed by using the unpaired two-sample t test or Mann-Whitney U test for continuous data, and the chi-square test or Fisher exact test for binary variables. Data are presented as the mean value Ϯ SD. The follow-up data on heart size and function (LVEDD, SF and CT ratio) were analyzed with linear regression. A p value Ͻ0.05 was considered statistically significant.
RESULTS
Clinical characteristics of study cohort. There were significant demographic differences between the patients with isolated CCAVB (n ϭ 102) and those with CCAVB who subsequently developed DCM (n ϭ 9) ( Table 1) . The age at diagnosis of CCAVB differed significantly between the groups (CCAVB: 24 Ϯ 45 months; CCAVB/DCM: 23 Ϯ 1 weeks gestation; p Ͻ 0.001). The average heart rate measured at birth was significantly lower in the patients with CCAVB and DCM. The mean length of follow-up was similar between the two groups (CCAVB: 10.1 Ϯ 6 years; CCAVB/DCM: 10 Ϯ 6.1 years; p Ͼ 0.10). The SSA/Ro and SSB/La antibodies were identified in 40 (77%) of 52 patients with CCAVB who did not develop DCM. Laboratory studies were not performed in the remaining 50 patients with CCAVB.
Dilated cardiomyopathy was diagnosed in nine patients (8%) at 6. Table 2 ). Five of the nine patients with DCM were delivered by cesarean section. Hydrops was observed in one patient. Maternal laboratory studies confirmed SSA/Ro and SSB/La antibodies in seven (78%) of these nine patients. In one patient, no antibodies were identified, and in the one remaining patient, no tests were performed. No other features of the neonatal lupus syndrome were noted. Signs and symptoms at the time of diagnosis of DCM included congestive heart failure (n ϭ 8), increasing fatigue with exertion (n ϭ 5), chest pain (n ϭ 2), dyspnea (n ϭ 4) and/or poor feeding (n ϭ 2). Physical examination findings revealed hepatomegaly (n ϭ 3), hyperactive precordium (n ϭ 3), crepitations (n ϭ 2) and/or poor perfusion of the lower extremities (n ϭ 2). No patient with DCM had a history suggestive of familial cardiomyopathy.
Echocardiograms at the time of diagnosis of DCM revealed LVEDD measurements in the Ͼ97th percentile, with SF of 11 Ϯ 5%. Chest radiographs at the time of Six of these nine patients did well initially on medical treatment, but the SF diminished with duration of follow-up (Fig. 2) . The LVEDD measurements were Ն97th percentile during follow-up of the patients with DCM. Two patients died within two months of the diagnosis, secondary to multiorgan system failure. Two other patients received a heart transplant three months and 7.5 years after the initial diagnosis. Four patients with DCM are currently awaiting heart transplantation. One patient was resuscitated shortly after the diagnosis and is neurologically compromised. The indication for pacemaker implantation in the DCM group included: 1) heart rate Ͻ50 beats/min (n ϭ 5, 56%); 2) progressive bradycardia noted on ambulatory monitoring (n ϭ 1, 11%); and 3) congestive heart failure (n ϭ 3, 33%).
Isolated premature ventricular contractions were observed in six patients (67%). However, no patient in the CCAVB/ DCM group had higher grade ectopy, including couplets or salvos of ventricular tachycardia. An endocardial device was implanted in two patients, and an epicardial system in seven patients.
Indication for pacing in the 102 patients with CCAVB included: 1) heart rate Ͻ50 beats/min (n ϭ 48, 47%); 2) progressive bradycardia (n ϭ 10, 10%); 3) syncope (n ϭ 11, 11%); 4) pauses Ͼ3.5 s seen on ambulatory monitoring (n ϭ 12, 11%); 5) exercise intolerance (n ϭ 10, 10%); and 6) heart failure (n ϭ 11, 11%). Isolated premature ventricular contractions were seen in 22 patients (21%), and ventricular couplets in six (6%). Ventricular tachycardia was not observed. Endocardial devices were initially implanted in 46 patients with CCAVB, and epicardial leads in 56 patients.
There was no significant difference in the type of pacing employed between the two study cohorts. Dual-chamber pacemakers were implanted in two patients with CCAVB and DCM (22%) and in 39 patients with CCAVB (38%). Single-ventricular chamber pacing was employed in the A ϭ alive; CHF ϭ congestive heart failure; CT ϭ cardiothoracic; D ϭ dead; DCM ϭ dilated cardiomyopathy; F ϭ female; HR ϭ heart rate; LVEDD ϭ left ventricular end-diastolic dimension; M ϭ male; PM ϭ pacemaker; SF ϭ shortening fracture. 
remaining 7 patients with CCAVB and DCM (78%) and in 63 patients with CCAVB (62%). Re-implantations were indicated in six patients with CCAVB and DCM (67%) and in 80 patients with CCAVB (78%, p Ͼ 0.10) due to generator depletion or lead failure. Echocardiographic measurements. Initial echocardiograms at the time of CCAVB diagnosis were obtained in 94 patients (85%) (CCAVB/DCM: n ϭ 7; CCAVB: n ϭ 87) ( Table 3 ). The initial LVEDD (CCAVB/DCM: 96th percentile Ϯ 2.6%; CCAVB: 76th percentile Ϯ 24%; p Ͻ 0.005), without a significant difference in LV function (CCAVB/DCM: 36 Ϯ 5.2%; CCAVB: 39 Ϯ 7.9%; p Ͼ 0.10).
Mild mitral regurgitation was seen in four patients with DCM and persisted on serial echocardiograms during follow-up. Initial LVEDD values Ͼ97th percentile were measured in 22 patients with CCAVB (21%) and showed a decrease in LVEDD Ͻ97th percentile within 4 Ϯ 3.5 years after pacemaker implantation. The initial SF in these patients was 38 Ϯ 7.1%. Over 6.5 Ϯ 5 years, the nine patients with CCAVB who eventually developed DCM continued to have a LVEDD Ͼ97th percentile Ϯ 1.8%, as well as a decrease in SF from 35.8 Ϯ 5.1% to 11 Ϯ 5%. This was significantly different from the CCAVB cohort (n ϭ 102), which showed a significant decrease in LVEDD to the 65th percentile Ϯ 20% (p Ͻ 0.001), without a change in LV function (36 Ϯ 3.6%, p Ͻ 0.01) 7 Ϯ 6 years after pacing. A decrease in heart size was initiated within two months (range 1 month to 1 year) after pacemaker implantation. Radiographic features. Initial chest radiographs were available for all nine patients who eventually developed DCM (Table 3 ). There was no radiographic evidence of pulmonary venous congestion, edema or atelectasis. All nine patients had cardiomegaly, graded as mild (n ϭ 4), moderate (n ϭ 2) or severe (n ϭ 3). An initial CT ratio of 64 Ϯ 3.8% was measured in the CCAVB/DCM group and remained relatively constant over 6.5 Ϯ 5 years at 63 Ϯ 6.8%. Mild vascular congestion and perihilar edema were observed in two patients on the initial chest radiographs and at mid-term follow-up.
The CT ratio in the CCAVB group decreased significantly with initiation of pacing from 57 Ϯ 7.2% to 49 Ϯ 6.3% (p Ͻ 0.01) over 7.5 Ϯ 4.6 years of follow-up. This decrease in the CT ratio was not seen in the CCAVB/ DCM group during a similar follow-up period.
DISCUSSION
Dilated cardiomyopathy. Dilated cardiomyopathy is a heterogeneous group of myocardial diseases characterized by dilation and impaired systolic function of the heart (5,10). Although specific causes can be identified, such as myocarditis, familial cardiomyopathies, endocardial fibroelastosis and metabolic disorders, most cases are idiopathic (11) (12) (13) . Similarly, no additional etiologic event could be identified in the nine patients with isolated CCAVB who eventually developed DCM. SSA/Ro and SSB/La autoantibodies. The SSA/Ro and SSB/La antibodies have been suggested to be a major determinant (1, 2) in the patients with CCAVB who eventually developed DCM. Evidence for a potential immunopathologic role of the SSA/Ro and SSB/La antibodies in CCAVB is described in several studies (3, 4) . Immunofluorescent studies have shown immunoglobulin G deposition throughout the myocardium on postmortem examination (14, 15) . Taylor et al. (16) demonstrated maternal antibodies directed against fetal cardiac tissue. Although these studies suggest a strong relationship between SSA/Ro and SSB/La antibodies and subsequent DCM (1, 2, 17) , the actual mechanism of the disease process has not yet been documented. The SSA/Ro and SSB/La antibody-mediated AV block was confirmed in seven of the nine patients who developed DCM. However, 40 of 52 tested patients with CCAVB who did not develop DCM were also SSA/Ro-and SSB/ La-positive. Thus, antibody positivity is not predictive in those patients with CCAVB who developed DCM. Adenine nucleotide translocator deficiency. Although myocardial biopsies did not provide any specific information on DCM, skeletal muscle biopsies in one patient revealed a deficiency of ANT, which is associated with Sengers' syndrome (10) . Sengers' syndrome consists of a triad of congenital cataracts, mitochondrial myopathy and hypertrophic cardiomyopathy and is not known to cause DCM (18) . This observation may be described as a new clinical finding and warrants further investigation. Pacemaker implantation. A previous study indicates that at least 10% of SSA/Ro and SSB/La antibody-associated patients with CCAVB do not respond favorably to pacemaker implantation, secondary to more diffuse cardiac involvement (2) . This study observed a similar incidence (9 [8%] of 111 patients) whereby pacemaker implantation did not decrease the LVEDD. Although cardiomegaly is a common feature in the CCAVB population, severe dilation of the LV is rare (8) . Some reports postulate that the increased heart size may be related to LV remodeling and reorganization of myofibers, secondary to an increase in Table 2 .
